Stent company Medinol Ltd. has presented positive results on its new cobalt chromium bare metal stent systems to the EuroPCR 2011 Congress in Paris. The company, owned and run by Dr. Judith Richter and Dr. Kobi Richter, examined use of the stent in a 278-patient multi-center, prospective, single-arm study conducted at 16 sites in Europe and Israel. Medinol reported that the results were comparable with stents already on the market. The new stents feature important technological advances designed to help restore the artery's natural form, support it to minimize the probability of restenosis and ensure easier access to distal lesions
The stent, known as Presillion, will be marketed by Johnson and Johnson. The stent is not covered by any medication, and will compete with the 30% uncovered stent market segment.
The US Food and Drug Administration (FDA) has already awarded the stent the fast-track status designed for breakthrough technologies.
Johnson & Johnson already markets Cypher stents in the US, but this will be the healthcare company's first uncovered stent.
Published by Globes, Israel business news - www.globes-online.com - on May 19, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011